Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian Cancer

SIMPLE SUMMARY: The therapeutic effect of Poly-ADP-ribose polymerase (PARP) inhibitor has been demonstrated in ovarian cancer patients with BRCA mutation or homologous recombination deficiency (HRD). HRD analysis at diagnosis determines treatment eligibility in ovarian cancer. In classifying the HRD...

Descripción completa

Detalles Bibliográficos
Autores principales: Paik, E Sun, Chang, Ha Kyun, Lee, Sanghoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296621/
https://www.ncbi.nlm.nih.gov/pubmed/37370704
http://dx.doi.org/10.3390/cancers15123095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296621/
https://www.ncbi.nlm.nih.gov/pubmed/37370704
http://dx.doi.org/10.3390/cancers15123095

Ejemplares similares